MUMBAI, June 30 (Reuters) - Drug maker Lupin Ltd LUPN.BO said on Tuesday it acquired the worldwide rights for AllerNaze, a branded steroid nasal spray, from Collegium Pharmaceutical Inc.
Financial details of the deal were not disclosed.
Lupin will initially launch the product, used to treat nasal symptoms associated with allergic rhinitis, in the United States, the company said in a statement to the Bombay Stock Exchange. (Reporting by Bharghavi Nagaraju; Editing by Prem Udayabhanu)
Our Standards: The Thomson Reuters Trust Principles.